Used in the treatment of certain types of leukemia, Tasigna has serious side effects that patients say they were never made aware of. Because of these potentially fatal side effects, our Tasigna arteriosclerosis lawsuit attorneys are filing suits seeking redress on behalf of patients and their families. Tasigna has been associated with a serious and potentially life-threatening condition known as atherosclerosis.

Tasigna Associated with Rapidly Progressing and Irreversible Atherosclerosis

Atherosclerosis is also known as hardening of the arteries, and it is the primary cause of stroke, peripheral vascular disease, and heart attack. Atherosclerosis causes your arteries to lose their flexibility and become hard and thick with plaque. This plaque buildup reduces how much blood flows through to the arteries that feed oxygen and nutrients to critical organs and tissue. As plaque continues to build, pieces can break free and travel through the bloodstream where they can cause dangerous clots that can block arterial blood flow.

Patients who are diagnosed with atherosclerosis may suffer potentially life-threatening conditions including:

• Carotid artery disease caused by reduced or blocked blood flow to the brain and may result in the patient suffering a stroke.
• Coronary artery disease caused by reduced blood flow to the heart and may result in heart attack.
• Peripheral artery disease cause by reduced blood flow to the legs and feet or arms and hands and may result in gangrene and amputation.

Novartis Failed to Warn of Dangers

Patients who developed rapidly progressing and potentially-fatal arteriosclerosis want to know when Novartis knew about the increased risks of hardening of the arteries and why the company chose not to warn the medical community and its patients about these risks, especially since Novartis did warn patients and healthcare providers in other countries including Canada. In fact, Novartis issued warnings about the increased risks of hardened arteries in the information packets they provided doctors and patients, and on the Novartis Canada and Health Canada websites.

Patients want to know why Novartis failed to adequately warn them and their doctors about the association between Tasigna and atherosclerosis even while adverse event reports continued to mount. In fact, the FDA has received 13,645 Tasigna adverse event reports, of which serious injury was reported in 9563 cases, and deaths were reported in 2533 cases.

How We Help

Those patients who were diagnosed with atherosclerosis, or who suffered heart attack, stroke, gangrene, or amputations, and the families of those who died after receiving treatment with Tasigna want to know why Novartis failed to warn of the risks of hardened arteries and chose instead to tout the medication as a safer alternative to therapies that do warn of side effects, complications, and risks. If you or a CML patient you love suffered serious injury after being treated with Tasigna, including heart attack, stroke, tissue death, amputation, or death, we can help you hold Novartis accountable for its product and the injuries that product caused. Contact us today to learn more about Tasigna dangers and whether you are entitled to seek compensation for your injuries and losses.